dc.contributor.author | Patel, B | en_US |
dc.contributor.author | Kirkland, KE | en_US |
dc.contributor.author | Szydlo, R | en_US |
dc.contributor.author | Pearce, RM | en_US |
dc.contributor.author | Clark, RE | en_US |
dc.contributor.author | Craddock, C | en_US |
dc.contributor.author | Liakopoulou, E | en_US |
dc.contributor.author | Fielding, AK | en_US |
dc.contributor.author | Mackinnon, S | en_US |
dc.contributor.author | Olavarria, E | en_US |
dc.contributor.author | Potter, MN | en_US |
dc.contributor.author | Russell, NH | en_US |
dc.contributor.author | Shaw, BE | en_US |
dc.contributor.author | Cook, G | en_US |
dc.contributor.author | Goldstone, AH | en_US |
dc.contributor.author | Marks, DI | en_US |
dc.date.accessioned | 2024-01-04T14:41:25Z | |
dc.date.issued | 2009-10 | en_US |
dc.identifier.issn | 0390-6078 | en_US |
dc.identifier.uri | https://qmro.qmul.ac.uk/xmlui/handle/123456789/93383 | |
dc.format.extent | 1399 - 1406 | en_US |
dc.relation.ispartof | HAEMATOL-HEMATOL J | en_US |
dc.subject | adult acute lymphoblastic leukemia | en_US |
dc.subject | stem cell transplantation | en_US |
dc.subject | T-cell depletion | en_US |
dc.subject | BONE-MARROW-TRANSPLANTATION | en_US |
dc.subject | VERSUS-HOST-DISEASE | en_US |
dc.subject | INDUCTION THERAPY | en_US |
dc.subject | RANDOMIZED-TRIAL | en_US |
dc.subject | GRAFT-REJECTION | en_US |
dc.subject | IN-VIVO | en_US |
dc.subject | DEPLETION | en_US |
dc.subject | ANTIBODIES | en_US |
dc.subject | CHILDREN | en_US |
dc.subject | REGIMEN | en_US |
dc.title | Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission | en_US |
dc.type | Article | |
dc.identifier.doi | 10.3324/haematol.2009.008649 | en_US |
pubs.issue | 10 | en_US |
pubs.notes | Not known | en_US |
pubs.volume | 94 | en_US |
rioxxterms.funder | Default funder | en_US |
rioxxterms.identifier.project | Default project | en_US |